Abstract

The leading cause of death worldwide is cancer. Many reports have proved the beneficial effect of mushrooms in cancer. However, the precise mechanism is not completely clear. In the present study, we focused on the medicinal properties of biomolecules released by fairy ring-forming mushrooms. Fairy chemicals generally stimulate or inhibit the growth of surrounding vegetation. In the present study, we evaluated whether fairy chemicals (2-azahypoxanthine, 2-aza-8-oxohypoxanthine, and imidazole-4-carboxamide) exert anticancer activity by decreasing the expression of Axl and immune checkpoint molecules in melanoma cells. We used B16F10 melanoma cell lines and a melanoma xenograft model in the experiments. Treatment of melanoma xenograft with cisplatin combined with imidazole-4-carboxamide significantly decreased the tumor volume compared to untreated mice or mice treated cisplatin alone. In addition, mice treated with cisplatin and imidazole-4-carboxamide showed increased peritumoral infiltration of T cells compared to mice treated with cisplatin alone. In vitro studies showed that all fairy chemicals, including imidazole-4-carboxamide, inhibit the expression of immune checkpoint molecules and Axl compared to controls. Imidazole-4-carboxamide also significantly blocks the cisplatin-induced upregulation of PD-L1. These observations point to the fairy chemical imidazole-4-carboxamide as a promising coadjuvant therapy with cisplatin in patients with cancer.

Highlights

  • Cancer is the most frequent cause of death worldwide, according to the World HealthOrganization [1]

  • Previous studies have shown that cisplatin upregulates the expression of programmed death-ligand 1 (PD-L1) in cancer cells [40,41,42]

  • We evaluated whether the fairy chemical ICA can decrease the expression of PD-L1 induced by cisplatin in B16F10 melanoma cells

Read more

Summary

Introduction

Cancer is the most frequent cause of death worldwide, according to the World HealthOrganization [1]. The development of small-molecule inhibitors of receptor tyrosine kinase activation caused by cancer driver genes and immunotherapy targeting immune checkpoint molecules that stimulate the host immune system to kill malignant cells are some of the greatest achievements in the field of cancer therapy [2,3,4,5,6]. Increased expression and activation of Axl contribute to primary and acquired drug resistance by stimulating mesenchymal differentiation and survival of cancer cells and suppressing the host immune response [13,14,15,16]. Axl activation can promote the expression of immune checkpoint molecules and tumor growth [17] These observations point to Axl as an important target for overcoming cancer drug resistance

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call